Opinion|Videos|January 2, 2025
Metastatic Site–Specific Outcomes With 1L ccRCC Therapies
Author(s)Viktor Grünwald, MD, PhD, Martin H. Voss, MD
Panelists discuss how metastatic site–specific outcomes with first-line therapies for clear cell renal cell carcinoma (ccRCC) provide insights into the efficacy of treatment strategies based on the location of metastases.
Advertisement
Episodes in this series
Advertisement
Related to this article
Matthew Matasar, MD, reflected on how quickly oncology has moved from skepticism to nimble adoption of AI, and what he expects from the field going forward.
Advertisement
Advertisement
Trending on CancerNetwork
1
Trastuzumab Botidotin Prolongs PFS vs T-DM1 in HER2+ Advanced Breast Cancer
2
Daraxonrasib Receives FDA Breakthrough Therapy Status in 1L Metastatic PDAC
3
How Does Azacitidine/Venetoclax Impact Hospital Burden in AML?
4
IASO208 Receives FDA IND Clearance for Relapsed/Refractory B-Cell Lymphoma
5